Evaluation of Possible Ways the Body May Process Two Different Forms of Elinzanetant in Healthy Study Participants
8 agosto 2026 aggiornato da: Bayer
A Combined Single- and Multiple-dose, Open-label, Randomized, 2 x 2 Crossover Study to Investigate the Relative Bioavailability of Two Oral Elinzanetant (BAY 3427080) Formulations in Healthy Female Participants
This study is being done to compare two forms of the medicine elinzanetant, which is used to help manage hot flush symptoms related to changes in female hormones. The researchers want to find out whether a new tablet form of elinzanetant is absorbed and processed by the body of healthy women in a similar way than an existing capsule form.
About 100 healthy women aged 18 to 65 will take part in this study. Each participant will receive both forms of the medicine at different times during the study. They will take the medicine once daily for several days under controlled conditions at a study center, and blood samples will be collected to measure how the body absorbs and handles the drug. The study is designed so that each participant can be compared to herself, helping researchers clearly understand any differences between the two formulations.
Panoramica dello studio
Stato
Reclutamento
Intervento / Trattamento
Tipo di studio
Interventistico
Iscrizione (Stimato)
100
Fase
- Fase 1
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Contatto studio
- Nome: Bayer Clinical Trials Contact
- Numero di telefono: (+)1-888-84 22937
- Email: clinical-trials-contact@bayer.com
Luoghi di studio
-
-
Quebec
-
Mount Royal, Quebec, Canada, H3P 3P1
- Reclutamento
- Altasciences
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Sì
Descrizione
Inclusion Criteria:
- Female participants aged 18 to 65 years (inclusive) at the time of signing informed consent.
- Participants must be overtly healthy as determined by the investigator based on medical history, physical examination, vital signs, ECG, and clinical laboratory assessments.
- Body weight ≥50 kg and body mass index (BMI) between 18.0 and 32.0 kg/m² (inclusive) at screening.
- Women of childbearing potential must agree to use a highly effective method of contraception during the study and until 14 days after last administration of study intervention.
- Signed informed consent obtained prior to any study-specific procedures.
Exclusion Criteria:
- Diseases or conditions that may affect absorption, distribution, metabolism, elimination, or effects of the study intervention(s).
- Known or suspected hypersensitivity to the study intervention(s) or their excipients.
- Severe allergies or clinically significant hypersensitivity reactions (e.g. allergic asthma, urticaria, or steroid-requiring allergies).
- Febrile illness within 2 weeks prior to first administration of study intervention.
- History of clinically relevant seizures or endometrial tumors.
- Use of moderate or strong CYP3A4 inhibitors or inducers within 4 weeks prior to first study intervention.
- Participation in another clinical study within 30 days prior to first study intervention or concurrent participation in another trial.
- Clinically relevant abnormal laboratory findings at screening, including elevated liver enzymes or positive virology tests.
- Positive pregnancy test at screening or prior to dosing, or breastfeeding. Positive drug abuse or alcohol test at screening.
- Smoking more than 10 cigarettes per day within 3 months prior to screening.
- Special diets incompatible with study requirements or inability to comply with study procedures.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Sequence 1: Treatment A followed by Treatment B
Participants receive Treatment A followed by Treatment B in a randomized 2 x 2 crossover design with two treatment periods.
|
Elinzanetant treatment A is administered orally once daily.
Elinzanetant treatment B is administered orally once daily.
|
|
Sperimentale: Sequence 2: Treatment B followed by Treatment A
Participants receive Treatment B followed by Treatment A in a randomized 2 x 2 crossover design with two treatment periods.
|
Elinzanetant treatment A is administered orally once daily.
Elinzanetant treatment B is administered orally once daily.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Area Under the Plasma Concentration-Time Curve Over 24 Hours After Multiple Dosing (AUC(0-24)md)
Lasso di tempo: On Day 11 of each 12-day treatment period (study intervention administered on Days 1-10)
|
elinzanetant administered in the evening 3 hours after a light dinner.
|
On Day 11 of each 12-day treatment period (study intervention administered on Days 1-10)
|
|
Maximum Observed Plasma Concentration After Multiple Dosing (Cmax,md)
Lasso di tempo: On Day 11 of each 12-day treatment period (study intervention administered on Days 1-10)
|
elinzanetant administered in the evening 3 hours after a light dinner.
|
On Day 11 of each 12-day treatment period (study intervention administered on Days 1-10)
|
|
Minimum Observed Plasma Concentration During Dosing Interval After Multiple Dosing (Cmin,md)
Lasso di tempo: On Day 11 of each 12-day treatment period (study intervention administered on Days 1-10)
|
elinzanetant administered in the evening 3 hours after a light dinner.
|
On Day 11 of each 12-day treatment period (study intervention administered on Days 1-10)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number and Severity of Treatment-Emergent Adverse Events (TEAEs)
Lasso di tempo: From first dose of study intervention through Day 12 of Period 2 (each treatment period is 12 days)
|
From first dose of study intervention through Day 12 of Period 2 (each treatment period is 12 days)
|
|
|
Area Under the Plasma Concentration-Time Curve Over 24 Hours After Single Dose (AUC(0-24))
Lasso di tempo: On Day 2 of each 12-day treatment period
|
elinzanetant administered in the evening under fasted conditions.
|
On Day 2 of each 12-day treatment period
|
|
Maximum Observed Plasma Concentration After Single Dose (Cmax)
Lasso di tempo: On Day 2 of each 12-day treatment period
|
elinzanetant administered in the evening under fasted conditions.
|
On Day 2 of each 12-day treatment period
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
22 luglio 2026
Completamento primario (Stimato)
22 febbraio 2027
Completamento dello studio (Stimato)
22 febbraio 2027
Date di iscrizione allo studio
Primo inviato
15 luglio 2026
Primo inviato che soddisfa i criteri di controllo qualità
8 agosto 2026
Primo Inserito (Effettivo)
13 agosto 2026
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
13 agosto 2026
Ultimo aggiornamento inviato che soddisfa i criteri QC
8 agosto 2026
Ultimo verificato
1 agosto 2026
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- 22791
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
NO
Descrizione del piano IPD
Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing".
This pertains to scope, timepoint and process of data access.
As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research.
This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.
Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research.
Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
prodotto fabbricato ed esportato dagli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .